JP2022553464A5 - - Google Patents
Info
- Publication number
- JP2022553464A5 JP2022553464A5 JP2021537127A JP2021537127A JP2022553464A5 JP 2022553464 A5 JP2022553464 A5 JP 2022553464A5 JP 2021537127 A JP2021537127 A JP 2021537127A JP 2021537127 A JP2021537127 A JP 2021537127A JP 2022553464 A5 JP2022553464 A5 JP 2022553464A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- peptide linker
- cancer
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025088503A JP2025143248A (ja) | 2019-10-24 | 2025-05-28 | 多重特異性抗体とその製造方法および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911015236.1 | 2019-10-24 | ||
| CN201911015236.1A CN110669137B (zh) | 2019-10-24 | 2019-10-24 | 一种多特异性抗体及其制备方法和用途 |
| PCT/CN2020/100892 WO2021077806A1 (zh) | 2019-10-24 | 2020-07-08 | 一种多特异性抗体及其制备方法和用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088503A Division JP2025143248A (ja) | 2019-10-24 | 2025-05-28 | 多重特異性抗体とその製造方法および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553464A JP2022553464A (ja) | 2022-12-23 |
| JP2022553464A5 true JP2022553464A5 (cg-RX-API-DMAC10.html) | 2023-07-19 |
Family
ID=69083964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537127A Pending JP2022553464A (ja) | 2019-10-24 | 2020-07-08 | 多重特異性抗体とその製造方法および使用 |
| JP2025088503A Pending JP2025143248A (ja) | 2019-10-24 | 2025-05-28 | 多重特異性抗体とその製造方法および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088503A Pending JP2025143248A (ja) | 2019-10-24 | 2025-05-28 | 多重特異性抗体とその製造方法および使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12415852B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3868788A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2022553464A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220087402A (cg-RX-API-DMAC10.html) |
| CN (2) | CN110669137B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020371001A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021077806A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| CN113214406B (zh) * | 2020-01-21 | 2022-08-02 | 苏州普乐康医药科技有限公司 | 一种结合gpc3融合蛋白的制备方法及应用 |
| CN112336873B (zh) | 2020-08-04 | 2022-04-19 | 华南理工大学 | 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法 |
| CN114478788B (zh) * | 2020-11-11 | 2025-07-18 | 北京免疫方舟医药科技有限公司 | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 |
| CN117321079A (zh) * | 2021-01-11 | 2023-12-29 | 优特力克斯有限公司 | 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 |
| CN115505041B (zh) * | 2021-06-22 | 2026-05-05 | 北京免疫方舟医药科技有限公司 | 抗EphA2抗体及其应用 |
| CN113527503A (zh) * | 2021-07-27 | 2021-10-22 | 福建医科大学 | 一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白 |
| CN118556083A (zh) * | 2021-10-12 | 2024-08-27 | 乐普创一生物科技(上海)有限公司 | 具有改善的治疗指数的靶向cd3的t细胞衔接器 |
| CN114409797B (zh) * | 2021-12-24 | 2024-02-20 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
| CN116640224A (zh) * | 2022-02-16 | 2023-08-25 | 北京免疫方舟医药科技有限公司 | Cd137抗体和cd40l的融合蛋白及其应用 |
| CN114380917B (zh) * | 2022-03-25 | 2022-06-14 | 南京融捷康生物科技有限公司 | 针对IL-17A和TNFα的双特异性单域抗体及其用途 |
| CN115368448B (zh) * | 2022-07-19 | 2025-08-01 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| US20260116960A1 (en) * | 2022-09-29 | 2026-04-30 | Shanghai Hongcheng Biopharmaceutical Co., Ltd. | Trispecific antibodies targeting pd-1, ctla-4 and vegf and use thereof |
| CN115969997B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
| CN116987198B (zh) * | 2023-09-28 | 2023-12-26 | 军科正源(北京)药物研究有限责任公司 | 一种靶向人pd-l1的融合蛋白及其用途 |
| CN117843803B (zh) * | 2023-12-29 | 2024-11-29 | 北京贝来药业有限公司 | 串联单域抗体及其在疾病治疗中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| JPH07503124A (ja) * | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| CN100497390C (zh) * | 2003-06-27 | 2009-06-10 | 比奥根艾迪克Ma公司 | 疏水-相互作用-层析或铰链区修饰对于均质抗体溶液的制备的用途 |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| NZ603059A (en) * | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2281845B1 (en) | 2008-04-25 | 2020-09-02 | Kyowa Kirin Co., Ltd. | Stable polyvalent antibody |
| US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| KR101721301B1 (ko) | 2011-08-23 | 2017-03-29 | 로슈 글리카트 아게 | 이중특이적 항원 결합 분자 |
| KR101886983B1 (ko) | 2011-08-23 | 2018-08-08 | 로슈 글리카트 아게 | 2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법 |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| WO2015103549A1 (en) * | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| CN107172880B (zh) * | 2014-03-24 | 2021-09-28 | 癌症研究技术有限公司 | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 |
| KR20170017916A (ko) * | 2014-05-13 | 2017-02-15 | 추가이 세이야쿠 가부시키가이샤 | 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자 |
| GB201409558D0 (en) * | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| CN104592392B (zh) * | 2015-01-21 | 2018-08-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| AU2015366284B2 (en) * | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| HK1245662A1 (zh) * | 2014-12-19 | 2018-08-31 | Alexion Pharmaceuticals, Inc. | 治疗组织钙化的方法 |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| CN104558191B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd20×cd3的构建及应用 |
| GB201521393D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| CN109563166B (zh) * | 2016-04-28 | 2022-12-20 | 拜奥穆尼克斯制药 | 靶向egfr和her2的双特异性抗体 |
| WO2018098370A1 (en) | 2016-11-23 | 2018-05-31 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
| IL268995B2 (en) * | 2017-03-02 | 2024-02-01 | Nat Res Council Canada | TGF-B receptor ectodomain fusion compounds and their uses |
| CN107266567B (zh) * | 2017-06-05 | 2021-06-04 | 高新 | Lcrmp4单克隆抗体及其制备方法与应用 |
| AU2020283890A1 (en) * | 2019-05-30 | 2021-12-16 | Amgen Inc. | Engineering the hinge region to drive antibody dimerization |
| CN110669137B (zh) | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
-
2019
- 2019-10-24 CN CN201911015236.1A patent/CN110669137B/zh active Active
- 2019-10-24 CN CN202110525473.3A patent/CN113416258B/zh active Active
-
2020
- 2020-07-08 WO PCT/CN2020/100892 patent/WO2021077806A1/zh not_active Ceased
- 2020-07-08 US US17/292,739 patent/US12415852B2/en active Active
- 2020-07-08 JP JP2021537127A patent/JP2022553464A/ja active Pending
- 2020-07-08 EP EP20878020.5A patent/EP3868788A4/en active Pending
- 2020-07-08 KR KR1020217015906A patent/KR20220087402A/ko not_active Ceased
- 2020-07-08 AU AU2020371001A patent/AU2020371001A1/en active Pending
-
2025
- 2025-05-28 JP JP2025088503A patent/JP2025143248A/ja active Pending
- 2025-08-20 US US19/305,277 patent/US20260001947A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025143248A (ja) | 多重特異性抗体とその製造方法および使用 | |
| JP7348899B2 (ja) | 多重特異性分子及びその使用 | |
| US20220288200A1 (en) | Multispecific and multifunctional molecules and uses thereof | |
| AU2018224094B2 (en) | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof | |
| CN109906232B (zh) | 包含λ轻链和κ轻链的多特异性抗体分子 | |
| AU2017345791B2 (en) | Multimeric IL-15-based molecules | |
| JP7809639B2 (ja) | Mait及び腫瘍細胞の両方に結合する多重特異性抗体 | |
| CA3059769A1 (en) | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof | |
| CA3233075A1 (en) | Interleukin-2 mutant and fusion protein thereof | |
| JP2018537415A (ja) | 多価Fv抗体 | |
| MX2014000816A (es) | Molecula fv de union de antigeno multivalente. | |
| JP2024116283A (ja) | Cldn18.2及びcd3に結合する二重特異性結合剤 | |
| US20230295348A1 (en) | Composition and methods for the selective activation of cytokine signaling pathways | |
| EP4245774A1 (en) | Fusion protein targeting both cd3 and cd137, preparation method therefor and use thereof | |
| EA051393B1 (ru) | Биспецифические связывающие агенты, связывающиеся с cldn18.2 и cd3 | |
| HK40014316A (en) | Multimeric il-15-based molecules |